Poster P987 showed that isavuconazole is completely bioavailable, supporting early switch to the oral dosage form in the clinic. Some azoles can cause cardiac disturbances. Isavuconazole showed no QT prolongation in the study presented (P1675).
List of Ceftobiprole Presentations
P710 Baseline activity of ceftobiprole against methicillin-susceptible and -resistant staphylococcal clinical isolates from Europe collected in 2005-2006. T. Davies, D. Sahm, R. Flamm, K. Bush (Raritan, Herndon, U.S.)
P779 Pharmacokinetics of ceftobiprole following single and multiple intravenous infusions administered to healthy subjects. B. Murthy, D. Skee, D. Wexler, D. Balis, I. Chang, D. Desai-Kreiger, G. Noel (Raritan, U.S.)
P780 Activity of ceftobiprole tested against contemporary European Enterobacteriaceae and Pseudomonas aeruginosa (2005-2006). T. Fritsche, H. Sader, P. Strabala, R. Jones (North Liberty, U.S.)
P781 Activity of ceftobiprole tested against staphylococcal and streptococcal isolates recovered from patients in European medical centres (2005-2006). T. Fritsche, H. Sader, P. Strabala, R. Jones (North Liberty, U.S.)
P783 QT/QTc assessment of ceftobiprole in a single-dose study. D. Balis, R. Strauss, B. Murthy, H. Tiian, G. Noel (Raritan, U.S.)
P784 In vitro activity of ceftobiprole, dalbavancin and tigecycline against methicillin-resistant Staphylococcus aureus strains from hospitalised patients in Belgium. O. Denis, C. Nonhoff, A. Deplano, M. Hallin, R. De Ryck, S. Rottiers, S. Crevecoeur, M.J. Struelens (Brussels, BE)
P1321 Regional variation in Panton-Valentine leukocidin positivity among S. aureus isolates in complicated skin and skin structure infections. R. Strauss, K. Amsler, M. Jacobs, K. Bush, G. Noel (Raritan, U.S.)
P2024 Profile of ceftobiprole activity against S. aureus, S.
pneumoniae, Enterobacteriaceae, and P. aeru